Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABASTY trial of bi-weekly versus tri-weekly cabazitaxel in elderly men with metastatic castration-resistant prostate cancer
NL-OMON48773Phase 3Withdrawn
- Sponsor
- Al Rayyan Tourism Investment Company
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabazitaxel and prednisone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Al Rayyan Tourism Investment Company. Planned start Jun 2018; status: withdrawn.
02
Drugs
cabazitaxelprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON48773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48773.